Company Name, Ticker, Customers, else..

• Gross Margin

• EBITDA Margin

• Operating Margin

• Pre-Tax Margin

• Effective Tax Rate

• Free Cash Flow Margin

• Cash Flow Margin

Valuation Comparisons

Management Effectiveness

Financial Strength

Dividend Comparisons

Abbott Laboratories (NYSE: ABT)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Abbott Laboratories Profitability Comparisons

Select each Category to receive further Information

Select the Comparisons :

Profitability ▼

Select the Ratio:

None▼

Profitability ▼

None▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ABT Profitability Ratio	Company	Industry	Sector	S&P 500
Gross Profit Margin (Q1 MRQ)	56.2 %	70.91 %	65.43 %	46.08 %
Gross Margin (Q1 TTM)	56.26 %	71.7 %	65.99 %	46.3 %
Gross Profit Margin 5 Yr. Avg.	56.03 %	67.81 %	65.55 %	48.95 %
EBITDA Margin (Q1 MRQ)	20.17 %	21.45 %	18.99 %	20.49 %
EBITDA Margin (Q1 TTM)	25.04 %	25.15 %	21.01 %	20.13 %
EBITDA Margin 5 Yr. Avg.	26.62 %	47.09 %	31.38 %	23.41 %
Operating Margin (Q1 MRQ)	12.05 %	17.27 %	16.58 %	16.05 %
Operating Margin (Q1 TTM)	17.07 %	20.33 %	17.81 %	16.34 %
Operating Margin 5 Yr. Avg.	17.86 %	15.37 %	14.33 %	19.26 %
Pre-Tax Profit Margin (Q1 MRQ)	12.98 %	13.66 %	10.94 %	13.96 %
Pre-Tax Profit Margin (Q1 TTM)	18.03 %	16.7 %	12.79 %	13.09 %
Pre-Tax Profit Margin 5 Yr. Avg.	18.1 %	12.98 %	10.37 %	13.52 %
Net Margin (Q1 MRQ)	9.65 %	10.09 %	8.15 %	11.42 %
Net Margin (Q1 TTM)	13.91 %	13.13 %	9.94 %	10.76 %
Net Margin 5 Yr. Avg.	18.65 %	5.79 %	6.08 %	10.8 %

Business Segment			Profit Margin

Nutritional Products			-
Diagnostic Products			-
Medical Devices			-
Other			-
United States			-
International			-
Established Pharmaceuticals			-
Established Pharmaceuticals Key Emerging Markets			-
Established Pharmaceuticals Other			-
Nutritional Products Pediatric Nutritionals			-
Nutritional Products Adult Nutritionals			-
Diagnostic Products Core Laboratory			-
Medical Devices Rhythm Management			-
Medical Devices Electrophysiology			-
Medical Devices Heart Failure			-
Medical Devices Vascular			-
Medical Devices Structural Heart			-
Medical Devices Neuromodulation			-
Medical Devices Diabetes Care			-
United States Nutritional Products			-
United States Nutritional Products Pediatric Nutritionals			-
United States Nutritional Products Adult Nutritionals			-
United States Diagnostic Products			-
United States Diagnostic Products Core Laboratory			-
United States Medical Devices			-
United States Medical Devices Rhythm Management			-
United States Medical Devices Electrophysiology			-
United States Medical Devices Heart Failure			-
United States Medical Devices Vascular			-
United States Medical Devices Structural Heart			-
United States Medical Devices Neuromodulation			-
United States Medical Devices Diabetes Care			-
International Established Pharmaceuticals			-
International Established Pharmaceuticals Key Emerging Markets			-
International Established Pharmaceuticals Other			-
International Nutritional Products			-
International Nutritional Products Pediatric Nutritionals			-
International Nutritional Products Adult Nutritionals			-
International Diagnostic Products			-
International Diagnostic Products Core Laboratory			-
International Medical Devices			-
International Medical Devices Rhythm Management			-
International Medical Devices Electrophysiology			-
International Medical Devices Heart Failure			-
International Medical Devices Vascular			-
International Medical Devices Structural Heart			-
International Medical Devices Neuromodulation			-
International Medical Devices Diabetes Care			-
Other United States			-
Diagnostic Products Rapid and Molecular			-
Diagnostic Products Cancer Diagnostics			-
United States Diagnostic Products Rapid and Molecular			-
United States Diagnostic Products Cancer Diagnostics			-
International Diagnostic Products Rapid and Molecular			-
International Diagnostic Products Cancer Diagnostics			-

Company's Cashflow Profitability & Other

Profitability Ratios	Company	Industry	Sector	S&P 500
Free Cash Flow Margin (Q1 MRQ)	8.2 %	-0.01 %	0.21 %	1.39 %
Free Cash Flow Margin (Q1 TTM)	16.35 %	17.24 %	13.85 %	9.11 %
Free Cash Flow Margin 5 Yr. Avg.	-	19.28 %	14.86 %	15.58 %
Net Cash Flow Margin (Q1 MRQ)	-15.4 %	0.02 %	-0.02 %	0.13 %
Net Cash Flow Margin (Q1 TTM)	0.6 %	-0.66 %	0.13 %	1.85 %
Net Cash Flow Margin 5 Yr. Avg.	-	4.38 %	3.16 %	6.44 %
Effective Tax Rate (Q1 MRQ)	25.67 %	25.98 %	25.39 %	18.83 %
Effective Tax Rate (Q1 TTM)	22.87 %	21.21 %	22.93 %	19.44 %
Effective Tax Rate 5 Yr. Avg.	-	15.08 %	20.51 %	19.76 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.